Boehringer Ingelheim, Eli Lilly can resubmit NDA for diabetes drug with warning letter resolved

Eric Palmer Boehringer Ingelheim has finally received some good news for its manufacturing facility in Ingelheim, Germany. The FDA has notified it that it has closed out a warning ...

AstraZeneca trumpets diabetes duo’s victory in Phase III

Tracy Staton While its top executives were prepping for a hearing on Pfizer's megamerger offer, AstraZeneca rolled out new data from a diabetes trial. The verdict? A combination ...

GlaxoSmithKline wins an FDA nod for its GLP-1 diabetes drug albiglutide

Damian Garde After a three-month delay pushed pause on its commercial plans, GlaxoSmithKline has secured FDA approval for albiglutide, a new diabetes treatment that will contend for ...

In SGLT2 diabetes fight, Lilly’s empagliflozin loss is J&J and AstraZeneca’s gain

Tracy Staton Johnson & Johnson and AstraZeneca will just have to duke it out for share of the market for SGLT2 treatments for diabetes. A potential third competitor from Eli Lilly ...

Drug buyers sue Novo Nordisk over ‘wrongful’ delays to diabetes generic

Carly Helfand The Federal Trade Commission may now have the right to challenge pay-for-delay deals, but drugmakers can still stall the launches of competing generic products. And that's ...

UPDATED: FDA OKs AstraZeneca’s long-delayed diabetes drug dapagliflozin

John Carroll The FDA has handed AstraZeneca a green light to begin marketing dapagliflozin, its long-delayed SGLT2 diabetes drug, which will now try to defy ...

Takeda suffers a big blow to its diabetes pipeline with PhIII failure of TAK-875

John Carroll Takeda has suffered a major setback in its quest to fill the blockbuster gap left by last year's loss of patent protection for the diabetes drug Actos. The pharma company ...

FDA panel smiles on Bristol-Myers, AstraZeneca’s diabetes drug in do-over

Damian Garde Two years after a stinging rejection at the hands of the same committee, Bristol-Myers Squibb and AstraZeneca got a warmer reception for their diabetes drug dapagliflozin, ...

After Bristol-Myers R&D cuts, will AstraZeneca amp up its share of diabetes JV?

Tracy Staton When Bristol-Myers Squibb reported earnings last week, it seemed fully committed to AstraZeneca and their multibillion-dollar diabetes joint venture. Sales growth there ...

Bristol-Myers scores with cancer, diabetes sales hikes

Tracy Staton Bristol-Myers Squibb's third-quarter results amount to a good-news, bad-news report. On the positive side, international sales were up 18%, driving an overall increase ...

Who’d like Tom Hanks to be their diabetes role model?

Tracy Staton Look up the word "likable" in an actor's guidebook, and you'd find a picture of Tom Hanks. Ask his doctor, and you'd discover he has Type 2 diabetes. ...

Eli Lilly’s diabetes strategy doesn’t include big staff-up in sales

Tracy Staton As Lilly Diabetes President Enrique Conterno tells Bloomberg, the company plans to lean on its broad product portfolio to grow sales, rather than sending out legions of ...
Page 3 of 812345...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS